Want to get this daily news briefing by email? Here’s the sign-up.
WHAT WE’RE WATCHING
IMMUNE SUPPORT - The U.S. Food and Drug Administration’s full approval of the Pfizer-BioNTech coronavirus vaccine for people 16 and older could embolden more employers to require vaccination and certainly weakens employees’ attempts to litigate the issue. Still, getting the COVID-19 shot is like attending a Zoom happy hour, just because you can force your employees to do it, doesn’t necessarily mean you should. In this week’s Law.com Litigation Trendspotter column, we look at how Pfizer’s FDA approval has impacted the litigation landscape and why, despite the win for employers, attorneys still generally advise treading lightly when considering a vaccine mandate. I’m interested to hear what you think: should employers be mandating vaccines for their employees or do the potential cons—namely, harm to company culture and probable litigation—still outweigh the pros? Let me know at [email protected].
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
